We invite you to learn more about Iomab-B and Actimab-A.
Actinium Pharmaceuticals Inc. is a clinical-stage company that develops targeted therapies for superior targeted conditioning prior to a bone marrow transplant and for the targeted killing of cancer cells. Our Antibody Radio-Conjugates (ARC) combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Our most advanced ARC, Iomab-B, is an iodine-131 labeled anti-CD45 monoclonal antibody that is being evaluated in a pivotal Phase 3 trial for myeloablation prior to a bone marrow transplant for patients with r/r AML age 55+. Iomab-ACT is a low dose of Iomab-B for lymphodepletion prior to adoptive cell therapy. Our potentially best in class CD33 program uses an anti-CD33 monoclonal antibody ARC labeled with the alpha-particle emitter actinium-225. The CD33 program is currently being studied in multiple Phase 1 clinical trials for targeting conditioning, in combinations, and as a therapeutic in multiple diseases and indications including AML, MDS and MM. Our Antibody Warhead Enabling Technology Platform leverages our know how and intellectual property to create additional ARC candidates by labeling various targeting moieties with Ac225.
Brands: Iomab-B (Phase 3) for relapsed/refractory AML and BMT
Actimab-MDS (Phase 1/pivotal) for MDS and BMT
Actimab-M (Phase 1) for refractory Multiple Myeloma
Actimab-A + Venetoclax (Phase 1/2) for AML